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Rates of bacterial sexually transmitted infections (STIs) continue to rise, demanding 
treatments to be highly effective. However, curing infections faces significant challenges 
due to antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium and 
especially treating STIs at extragenital sites, particularly rectal chlamydia and oropharyngeal 
gonorrhoea. As no new antimicrobials are entering the market, clinicians must optimize the 
currently available treatments, but robust data is lacking on how the properties or 
pharmacokinetics of antimicrobials can be used to inform STI treatment regimens to 
improve treatment outcomes. This paper provides a detailed overview of the published 
pharmacokinetics of antimicrobials used to treat STIs and how factors related to the drug 
(tissue distribution, protein binding, half-life), human (pH, inflammation, site of infection, 
drug side effects, sexual practices) or organism (organism load, antimicrobial resistance) can 
affect treatment outcomes. As azithromycin is commonly used to treat chlamydia, 
gonorrhoea and Mycoplasma genitalium infections and its pharmacokinetics are well 
studied, it is the main focus of this review. Suggestions are also provided on possible dosing 
regimens when using extended and/or higher doses of azithromycin, which appropriately 
balance efficacy and side effects. The paper also emphasizes the limitations of currently 
published pharmacokinetic studies including oropharyngeal gonococcal infections where 
very limited data exists around ceftriaxone pharmacokinetics and its use in combination 
with azithromycin. In future, the different anatomical sites of infections may require 






Globally, the incidence of the three common bacterial sexually transmitted infections (STIs) 
chlamydia (Chlamydia trachomatis, CT), gonorrhoea (Neisseria gonorrhoeae; NG) and 
syphilis (Treponema pallidum) is high and the combined incidence is estimated to be over 
215 million new cases among adults (15-49 years) annually.1 There is also increasing concern 
about Mycoplasma genitalium (MG) infections, which are more common than NG, and in 
some countries have a similar burden to that of CT infections.2, 3 These STIs can result in 
considerable morbidity including reproductive complications in women, increase the risk of 
HIV transmission, and even cause mortality (e.g. congenital syphilis). 4 
Regular testing enables early detection of infections so that effective treatments can be 
given to break the onwards transmission and minimise the morbidity associated with 
infection. However, no single treatment is 100% effective as a result of host factors 
including patient compliance with taking treatment, vomiting or diarrhoea post-treatment, 
immune response, and organism factors such as antimicrobial resistance (AMR). 
There is increasing concern about antimicrobial treatment failure for several STIs. While 
bacterial AMR resulting in clinical failure in the treatment of chlamydia is rare or 
unverified,5, 6 there is considerable debate questioning the clinical efficacy of 1 gram 
azithromycin, particularly for rectal CT where repeat infection is common and thought to be 
frequently due to treatment failure.7 NG AMR is considered an urgent global threat by the 
World Health Organization with the organism being resistant to several classes of 
antimicrobials and dual antimicrobial therapy (mainly ceftriaxone 250-500 mg plus 
azithromycin 1-2 g) currently recommended as the last remaining option.8 MG has 
considerable problems with resistance to both first-line (azithromycin) and second-line 
(fluoroquinolones, mainly moxifloxacin) treatments.9 10 In contrast, syphilis continues to be 




reports of resistance to azithromycin when used in patients with β-lactam allergy and when 
doxycycline is contraindicated.11-13  
As concern for global AMR increases and few antimicrobials for STIs are in clinical 
development,14, 15 clinicians have little choice but to maximize the efficacy of currently 
available antimicrobials. One approach is to use higher doses or extended dosing regimens 
to improve treatment outcomes. However, to improve these dosing regimens an 
understanding of the pharmacokinetics of therapeutic antimicrobials, including the 
distribution of the drugs to the anatomical site of infection, is essential.  
In this paper, we provide a detailed overview of the published pharmacokinetic 
characteristics of STI antimicrobials and their impact on treatment efficacy. We highlight 
gaps in our understanding, with a special emphasis on oropharyngeal infections for which 
the greatest gaps exist, and discuss how treatment efficacy can be improved by considering 
the pharmacokinetic properties of antimicrobials. Since azithromycin is frequently used for 
treating CT,16 NG,17 and MG,9  there is a particular focus on this drug. As first-line treatment 
(benzathine penicillin G) for syphilis remains highly effective, this STI will not be further 
addressed.4  
 
Key pharmacokinetic parameters of antimicrobials  
Pharmacokinetics includes the broad areas of drug absorption, distribution, metabolism and 
excretion. The primary role of antimicrobial clinical pharmacokinetics is to enhance 
therapeutic efficacy, decrease drug toxicity, and avoid induction or selection of AMR. 
Once a drug is absorbed, either through the oral or parenteral route, it reaches a 
maximum concentration (Cmax) in the blood/tissues, after a certain time (time to maximum 




under the concentration-time curve over different time intervals: 0-24 hours (AUC0-24), and 
0-last time (AUC0-last) and/or 0-infinity (AUC0-∞), the latter corresponding to the estimated 
total exposure. At the simplistic level, antimicrobial efficacy is measured using 
pharmacokinetic/pharmacodynamic parameters such as the time the tissue/blood 
concentration of free drug exceeds the MIC of the microorganism (fT>MIC), the ratio of the 
maximum concentration to MIC (Cmax/MIC), and the ratio of the AUC to MIC (AUC/MIC).18 
Activity of antimicrobials is predominantly time-dependent (fT>MIC) for β-lactam 
antimicrobials (e.g. ceftriaxone) and concentration-dependent (Cmax/MIC and AUC0-24/MIC) 
for macrolides (e.g. azithromycin), tetracyclines (e.g. doxycycline)18 and fluoroquinolones 
(e.g. ciprofloxacin).  
Other pharmacokinetic characteristics of importance include bioavailablity, the volume 
of distribution (Vd) and the half-life (T1/2) of a drug. Bioavailability measures the fraction of 
an administered dose that reaches the systemic circulation. The Vd is the ratio of the dose 
present in the body and its plasma concentration, when the distribution of the drug 
between the tissues and the plasma is at equilibrium. In the case of an orally administered 
drug, this is influenced by the bioavailability of the drug. The larger the Vd, the greater the 
drug is distributed in the body. Azithromycin and doxycycline both have a very high Vd (>30 
L/kg), whereas the Vd is low for ceftriaxone (0.19 L/kg). The T1/2 is the time required for the 
concentration of drug to be reduced by 50% in the blood or tissue. T1/2 is a composite 
measure influenced by the Vd and clearance of the drug. It takes approximately 4-5 half-
lives for a drug to reach ‘steady state’ in the body with conventional dosing regimens i.e. 
when the rate of drug absorption and elimination are equal. Giving a higher first dose (a 




The key pharmacokinetic parameters for antimicrobials commonly used for treatment 




Table 1. Comparative pharmacokinetics of antimicrobials commonly used for treatment of sexually transmitted infections. 
 









 (Vd; L/kg) 




Bacteriostatic Oral: 37 2-3 68 31.1 Concentration dependent: 51% 
at 0.02 µg/mL to 7% at 2 µg/mL 
Bile/faeces 




0.1923 83-96 Bile/faeces  
(44% of dose) 
Doxycycline21 Bacteriostatic Oral: ~100 2-3 12-16 50 82-93 Urine  
(30-65% dose) 
Ciprofloxacin21 Bactericidal Oral: 60-70 1-2  5 3.2 20-40 Urine (40-50%) 
Cefixime21, 24 Bactericidal Oral: 40-50 2-6 3-4 1.1 70 Urine (50%) 






Factors affecting the pharmacokinetics and treatment efficacy of antimicrobials 
Drug solubility, molecular weight and protein binding 
In general, a drug that is more lipid soluble (in contrast to water soluble) such as 
azithromycin and doxycycline, penetrates across cellular membranes more readily which 
results in higher tissue penetration and therefore higher Vd. Drugs with low lipid solubility 
(e.g. gentamicin) will stay mainly in the blood compartment and have lower tissue 
penetration and Vd. Additionally, drugs of small sizes (low molecular weight) can cross 
cellular membranes more easily than higher molecular weight drugs.  
Drugs that are not bound to protein (i.e. free drug) are pharmacologically active and 
able to penetrate cells.25, 26 Protein binding for azithromycin is particularly interesting as 
unlike most other antimicrobials, protein binding among healthy individuals is dose-
dependent, decreasing from 51% at 0.02 µg/mL to 7% at 2 µg/mL,19 which suggests at high 
concentrations, protein binding will become saturated resulting in more free drug.  
 
pH effects 
Generally, unionised drugs are more lipid soluble and ionised drugs are more water soluble. 
The degree of ionisation (pKa) affects how much drug is absorbed across cellular 
membranes and pKa is affected by the pH of the tissue in which the drug is distributed. For 
example, azithromycin has a pKa of ~8.519 meaning at a pH of 8.5, 50% of the drug is ionised 
and 50% is unionised. Only the unionised form can permeate across cellular membranes and 
enter a cell,27 contributing to intracellular concentrations. A one unit increase in the pH 
from the pKa results in 91% of the drug being unionised, while a one unit decrease results in 




pH of 8 with a significant decrease in its efficacy at pH values <6.29 Therefore higher pH 
levels may be associated with greater tissue penetration leading to greater efficacy than 
lower pH levels. The pH of the human rectum has been shown to decrease (pH 8 to 7) as a 
result of inflammatory disease,30 but it is unknown whether inflammation from an STI 
infection can result in a similar decrease in pH thereby impacting on treatment efficacy. The 
implications for the vaginal site are much more complex. A vaginal pH of less than 4.5 is 
considered healthy31 and may inhibit chlamydia infection, although how this influences 
infection at the columnar epithelial surface is unknown.32 Bacterial vaginosis, which involves 
a profound shift in the vaginal microbiota to a dysbiotic state, is associated with a higher pH 
and an increased risk of acquiring other STIs.33 Inflammation associated with infection will 
also raise the vaginal pH. It is therefore plausible that higher pH in disease states improves 
the activity of azithromycin, which is less effective at lower pHs. Efficacy may also be related 
to the higher pH of the vaginal mucus (median pH of 7, range 5-8)34 and affected by factors 
such as menses and sex.35 It has previously been reported that CT treatment efficacy may be 
related to the concentration of azithromycin in the cervical mucus.36 
In the author’s study of the pharmacokinetics of azithromycin in rectal tissue,37 the 
highest tissue concentrations were observed in the participant who was on long term 
esomeprazole – a drug that raises intra-gastric pH by reducing acid production. This raises 
the possibility of role of local pH on the pharmacokinetics of azithromycin.  
 
Effects of inflammation  
STIs generate an immune response in the local tissue which may impact on the transport of 
drugs throughout the body.  For example, azithromycin is carried to the site of infection by 




(inflamed) gingiva compared with healthy gingiva (11.6 versus 6.3 µg/g; p<0.05)38 and in 
inflamed blisters compared with non-inflamed blisters (7.5 versus 4.5 mg.L/hr; p<0.02).39 
This suggests that using a higher first dose of azithromycin (‘front end loading’) with an 
acute infection when the inflammatory response is most pronounced and phagocytic cells 
are likely to be most abundant, may result in increased absorption and delivery to an 
infection site within the first 24 hours causing greater bacterial clearance.40 This property of 
azithromycin should be further exploited for STIs. 
 
Site of infection 
Evidence shows that drug efficacy can vary by site of infection. For example, azithromycin 
efficacy for CT appears to be lower in the anorectal site compared with the urogenital site7, 
41 and for NG, treatment efficacy is lowest for oropharyngeal infection. As outlined above, 
the pharmacokinetics and concentration of a drug can vary by the site of infection as a 
result of differences in pH of the tissue at the site of infection, protein binding or molecular 
weight. For example, only free drug or low molecular weight drugs can distribute into saliva 
which may or may not have an impact on treatment efficacy for oropharyngeal STIs.42 There 
is also evidence that the MIC of a drug can vary by infection site with a recent study finding 
that the CT MIC for azithromycin was about four times higher in a colorectal compared to an 
endocervical cell line, regardless of CT genovar.43 For STIs, it is essential that the 
antimicrobial used effectively distributes to all possible infection sites including 






Drug absorption from the oral route is more sensitive to external factors than drugs given 
parenterally. For a drug that has low oral bioavailability such as azithromycin (37%), factors 
that lower its absorption such as vomiting and diarrhoea remain critical for treatment 
efficacy. Studies show that for a 1 g dose of azithromycin, approximately 2% of subjects 
experience vomiting when given as a single dose but this is halved when the dose is divided 
over 3-5 days.19 NG treatment trials using azithromycin 2 g as a single dose as 
monotherapy44  or as part of dual therapies45 reported vomiting in 6-7% of people. In the 
author’s study of the rectal pharmacokinetics of azithromycin in men, the study found that 
men who experienced drug side effects such as diarrhoea had lower tissue concentrations,37 
which could contribute to treatment failure. 
Organism load 
Higher organism load has been associated with treatment failure for several STIs. For 
example, repeat CT infection following treatment with 1 g azithromycin suggestive of 
treatment failure has been associated with high organism load infections of the eye,46,47 
vagina,48 rectum,49 and pharynx.50  Another study examining the effectiveness of 
ciprofloxacin and doxycycline for treating chlamydia urethritis reported significantly higher 
ciprofloxacin treatment failure rate with infections of higher CT load, but no difference 
associated with doxycycline.51 There was no decreased ciprofloxacin susceptibility of the 
isolates before and after treatment and all patients with ciprofloxacin treatment failure 
were subsequently cured with seven days doxycycline (100mg twice per day) treatment for 
one week. For MG infections, higher pre-treatment organism loads have been reported 
among patients failing treatment with azithromycin,52 josamycin,53 and pristinamycin.54 
Further studies have used pre-treatment with doxycycline to reduce the MG load prior to 






Pre-sex rectal douching with non-isotonic fluids such as water is a common practice among 
MSM57 and the use hyperosmolar water-based lubricants have also been shown to cause 
damage to rectal tissue. Since azithromycin is likely to be found in rectal mucus and 
faeces,37 it is plausible that douching may have a reduce treatment efficacy for rectal STIs 
because douching may reduce local tissue exposure to drug laden faeces or mucus or may 
remove rectal cells containing azithromycin. 58-60 The author’s have previously shown that 
lower azithromycin rectal concentrations were found in men who practiced rectal 
douching.37 Observational studies also suggest that douching is associated with an increased 
risk of STIs.57, 61, 62  
 
Limitations of currently published pharmacokinetic studies 
Undertaking and interpreting the results of antimicrobial pharmacokinetic studies is 
challenging for the following reasons:   
i) Tissue concentrations do not always translate into clinical efficacy because of the 
drug’s relative distribution between different tissue compartments, including intracellular 
and extracellular compartments.63 This is further complicated because many studies have 
analysed tissue homogenates only, rather than determining the concentrations within the 
specific compartments where microorganisms reside, such as in the intracellular space for 
CT,64 NG,65, 66 and MG.67 Tissue sampling for pharmacokinetic studies is also prone to 
contamination (e.g. with blood, mucus, other cells) that can lead to overestimation of drug 
concentrations. In the author’s pharmacokinetics studies of 1 g azithromycin in rectal37 and 




intracellular and extracellular space and although the studies were able to report high 
concentrations of azithromycin, they were unable to report whether it was in the 
appropriate compartments for chlamydia infection. Further, the studies were unable to 
differentiate between azithromycin in mucus, blood or cervical/rectal epithelial cellular 
tissue. Being unable to clearly understanding the compartment in which the organism of 
interest resides, makes interpretation of results challenging.   
ii) MIC is an essential pharmacokinetic/pharmacodynamic parameter, but several 
factors impact on how accurately it is measured.  Firstly, variations in assay methods and  
bacterial strains can occur. 69 Secondly, as often observed with NG, MICs can change 
dramatically over time.70 Thirdly, MICs can vary by tissue type as highlighted when 
comparing azithromycin MIC for CT grown in colorectal versus endocervical cell lines.43  
iii) Many studies report total drug concentration only which does not differentiate 
between  protein-bound and free drug.71 Protein binding may be especially important for 
oropharyngeal infections because only free drug can distribute into saliva.72 
 
Distribution of drug into versus extracellular compartments and its impact on sub-
inhibitory antimicrobial levels 
Azithromycin 
Given it takes about five half-lives for drug concentrations to fall to negligible levels after 
treatment, patients treated with azithromycin will have a prolonged tail of sub-inhibitory 
concentrations (sub-MIC) both intra and extracellularly because of the drug’s long T1/2 (68 
hours). This means that the drug will be present for at least 2-4 weeks post treatment at 





One reason for azithromycin’s long intracellular half-life is that after it enters the acidic 
intracellular compartments the drug is trapped within the cell (ion trapping).26  While ion 
trapping helps to concentrate the drug intracellular at the site of infection, it does prevent 
the drug from diffusing back into the plasma. As a result, concerns remain about the 
presence of low concentrations in extracellular compartments where organisms may 
replicate,74 and where prolonged exposures to sub-inhibitory concentrations could induce 
or select azithromycin resistance.75  
 
We do not know what intracellular drug levels exert induction or selection pressure for 
resistance in different bacterial species. 26, 73, 76 As the MIC of azithromycin for MG is lower 
(0.002-0.008 mg/L) than that for NG (0.5 mg/L), it is likely that such an effect would be 
present for longer in-vivo with MG compared with NG. 77, 78 MG develops resistance very 
easily when using azithromycin monotherapy because it requires mutation of only one gene 
allele encoding the azithromycin target 23S rRNA. In contrast, NG requires a mutation in 
four alleles of the 23S rRNA gene.   
 
Dual therapy with an intracellular drug such as azithromycin together with an extracellular 
drug such as ceftriaxone is useful to target bacteria in both spaces. It has been reported that 
the AUC0-24/MIC90 for free azithromycin in extracellular compartment was sub-inhibitory for 
CT following a 500 mg dose.26 Given that sub-inhibitory concentrations might promote 
resistance emergence, it would be important to maximize bacterial kill as early as possible 
during treatment to clear all pathogens throughout the body (intracellularly and 
extracellularly) by using high loading doses and/or use dual therapy with antimicrobials that 




recommended dual therapy for gonorrhoea where ceftriaxone plus azithromycin are 
administered. The choice of loading dose should take the risk of vomiting and diarrhoea and 
the risk of reduced treatment efficacy into consideration.   
Dual therapy for NG using ceftriaxone plus azithromycin is widely recommended.79 
Ceftriaxone resistance is rare, particularly in azithromycin-resistant strains, so any 
developed azithromycin-resistant gonococcal cells are eradicated by the rapid bactericidal 
activity of ceftriaxone.79  With the exception of the UK, azithromycin resistance for NG has 
remained relatively low internationally80 and in several countries azithromycin resistance 
was already present or at higher levels prior to introduction of dual therapy. For example, in 
Europe, resistance to azithromycin (MIC>0.5 mg/L) was 13.2% in 2009 and 7.2% in 2010, but 
since dual treatment with ceftriaxone 500 mg and azithromycin 2 g was introduced in 2012, 
azithromycin resistance has remained stable at 7 to 8% since 2014. 81 The majority of 
azithromycin-resistant gonococcal isolates in Europe have an azithromycin MIC close to the 
resistance breakpoint10 and the clinical relevance of these low-level resistant azithromycin 
isolates remains unclear.  
 
A further complication of the long half-life of azithromycin is that repeat infection with NG 
and MG within 2-4 weeks of initial treatment with azithromycin may expose these STIs to 
sub-inhibitory concentrations that could theoretically promote induction or selection of 
macrolide resistance. While this is unlikely in low risk individuals, it is a strong probability in 
high risk populations such as MSM where repeat infection is common.82, 83 One large study 
(4660 isolates) reported no association between recent azithromycin exposure and 
increased azithromycin MICs in cultured gonococcal isolates,84 but this study was limited as 




exactly what treatment was prescribed as their national surveillance system did not capture 
prescribing information. Further, this study did not include rectal infections. However, data 
from the European gonococcal AMR surveillance shows that azithromycin resistance in 
rectal NG samples has been lower than that from urogenital and pharyngeal samples.85  
 
Ceftriaxone 
Increasing the ceftriaxone dose from 500 mg to 1 g to treat NG would extend the duration 
of ceftriaxone efficacy (fT>MIC) but may also result in sub-inhibitory levels. Studies have 
reported that following a 500 mg intramuscular (IM) dose, ceftriaxone was still detectable in 
urine 18-36 hours after administration,86, 87 suggesting reasonable tissue levels would still be 
present after 36 hours. After a 1 g IM dose, ceftriaxone was detected in tissue (nasal 
mucosa, tonsil and lung) after 24 hours88 and in plasma after 36 hours.22 Another study 
reported a serum half-life of 17.7 hours following a 1 g IM dose89 which would equate to 
88.5 hours (3.7 days) to clear ceftriaxone. Consideration of the half-life of a drug is 
important for two reasons. Firstly, ceftriaxone and/or azithromycin concentrations need to 
be above the MIC for sufficient time to kill NG. Secondly, residual concentrations may pose a 
risk to induce resistance with re-exposure at sub-MIC levels. A recent modelling paper 
following a 500 mg and a 1 g ceftriaxone dose reported effective concentrations for 
ceftriaxone susceptible gonococcal strains (MIC≤0.125 mg/L) in a patient for up to 33 hours 
and 41 hours, respectively.70 If a person is re-infected while azithromycin from the NG dual 
therapy remains present in sub-inhibitory concentrations intracellularly, levels would be 
insufficient to protect against induction or selection of macrolide resistance in NG. In 
contrast, the risk of inducing or selecting resistance to ceftriaxone is likely to be less, as the 






Extended doses may improve treatment efficacy 
It is likely that higher doses and/or extended dose regimens of antimicrobials will improve 
treatment efficacy,90, 91 by increasing fT>MIC, Cmax, decreasing the time to Cmax and 
increasing the overall AUC, thereby increasing the time the tissue concentrations are above 
the MIC for the organism. For example, higher doses of azithromycin of 1.5 g or more have 
been reported to be more effective at treating MG,55, 56  NG,44, 92 and CT.93 In designing 
extended dose regimens, it is important to ensure a balance between maximizing patient 
compliance with short courses, minimizing side effects by limiting any single dose, and 
maximizing effectiveness. It has been demonstrated that for any given total dose of 
azithromycin, administration as a single or a short course (e.g. duration of less than 3 days) 
provides similar or better outcomes compared to the same total dose given over a longer 
period. Data also show that higher systemic exposure of azithromycin was obtained when a 
total dose of 1.5g was given over 3 days instead of 5 days (19.4 versus 15.9 mg.h/L 
respectively; p=0.06).94 Additionally, exposure in the first 24 hours (AUC0-24) was 
approximately three-fold higher following a single 2 g azithromycin dose compared with a 
single 500 mg dose (9.3 versus 2.9 mg.h/L).95-97 Animal studies also report that ‘front end’ 
azithromycin dosing produced superior rates of bacterial clearance.40 These data suggest 
that the higher the first dose (or ‘loading’ dose), the greater the systemic exposure of 
azithromycin in the first 24 hours and thus the likelihood that the treatment will be more 
efficacious.  
While it makes sense that maximizing the first dose with a single 2 g azithromycin dose 




treatment efficacy, patient tolerance may be compromised with higher gastrointestinal side 
effects (35%44 versus 24%41 for 2 g and 1 g single dose respectively; p<0.01).56 It is important 
to consider other potential adverse events and the populations being treated with extended 
azithromycin regimens with one study finding a small increased risk of as cardiovascular 
death in older patients with pre-existing cardiovascular disease,98 although this was based 
on observational and not randomized controlled trial data. Nevertheless, the risks and 
benefits of extended azithromycin doses should be considered.   
 
Gaps in our understanding about the pharmacokinetics of antimicrobials for STIs – the 
example of oropharyngeal STIs 
The role of saliva in oropharyngeal STIs 
The pharmacokinetics of antimicrobials in the pharyngeal mucosa is complex and it is not 
clear what relative antimicrobial concentrations are required in tissue and saliva to cure 
oropharyngeal STIs, or even whether saliva concentrations are needed at all. 42 Further, little 
is known about the microbiology of STIs in the oropharynx. Take NG as an example.  It has 
been found intracellularly in tissue sections of tonsils, in cellular debri in tonsillar crypts, in 
tonsillar exudate and saliva but not in gingiva, buccal mucosa or the tongue.99  NG organism 
load has been shown to be similar between the pharnyges and saliva and it can be cultured 
from the saliva.100  However, there is little published information about where NG grows 
and replicates in the oropharynx and what tissues/compartments drugs need to target or 
what concentrations are needed to cure STIs.  We know even less about the microbiology of 
CT or MG in the oropharynx but saliva has also been reported to have an inhibitory effect on 
CT in-vitro.101 Yet this information is vital to ensure that oropharyngeal STIs are effectively 




determinants from co-colonising commensal Neisseria species or other micro-organisms.102, 
103 
Generally only free drug is able to effectively distribute into saliva.72 For bacteria that are 
found in saliva such as for NG saliva concentrations impact on treatment efficacy by acting a 
reservoir of untreated bacteria.104 Table 2 summarises the level of protein binding and 
relative concentrations in saliva compared to plasma of antimicrobials used currently or 
previously for STIs.  
Table 2: Relative concentrations of antimicrobials in saliva compared to plasma38, 42, 88, 90, 105, 
106 
 
Antibiotic Protein binding (%) Saliva to plasma ratio* 
Azithromycin 7-51** 6 
Gentamicin  <30 0.9 
Moxifloxacin 50 0.9 
Ofloxacin 32 Healthy: 0.8 
Sick: 1.4 
Amoxicillin 20 0.6 
Ciprofloxacin  20-40 0.5 
Cefixime 65 0.2 
Erythromycin 85 0.2 
Doxycycline 82-93 0.1 
Ceftriaxone 83-96 <0.004 
Penicillin V 80 0 (Not detected) 
* Ratio=drug concentration in saliva / drug concentration in plasma; approximate 








With respect to oropharyngeal NG, the data show that historical treatment with oral 
ciprofloxacin (having a high cure rate for ciprofloxacin susceptible pharyngeal NG), cefixime 
and amoxicillin (with probenecid) resulted in low saliva-plasma ratios of 0.6 or less. For 
injectable ceftriaxone, saliva-plasma ratios were even lower (<0.1) and ceftriaxone has been 
reported as undetectable in saliva22 but with concentrations in tonsils (tonsil-plasma ratio 
0.2).88 Accordingly, the high efficacy of ciprofloxacin and ceftriaxone to treat pharyngeal NG 
is likely related to high distribution into other tissue compartments and/or associated 
additionally with their rapid bactericidal activity. However, azithromycin reached high levels 
in saliva/gingiva38 (gingiva-plasma ratio of 17 and 31 for healthy and inflamed tissue, 
respectively) and tonsillar tissue (tonsil-plasma ratio of 150),107 suggesting high oral tissue 
penetration. This indicates that azithromycin may be highly effective for the treatment of 
oropharyngeal NG infections and possibly more effective than many other antimicrobials. 
However, one recent randomised controlled clinical trial (RCT) examining the use of 
injectable gentamicin 240 mg plus azithromycin 1 g for treatment of NG showed 94% cure 
rate for urogenital sites but only 90% for anogenital infections and 80% for pharyngeal 
infections.108 This may be related to the low distribution of gentamicin in saliva, but also 
that 1 g of azithromycin may be too low dose in dual NG therapy. In contrast, a RCT 
evaluating gentamicin 240 mg plus azithromycin 2 g reported 100% cure rate for urogenital 
infections (n=202) and few pharyngeal (n=10) and rectal (n=1) gonococcal infections 
although sample size for these last two sites was very small.45 This combination may have 
improved efficacy as azithromycin was used in a 2 g dose, and azithromycin is concentrated 
intracellularly and gentamicin extracellularly.109 RCTs including larger number of 
extragenital, particularly pharyngeal, infections and using higher dose azithromycin 




effects (especially vomiting56) in combination with ceftriaxone, gentamicin and possibly 
other antimicrobials would be valuable.  
Cellular and saliva turnover in mouth 
Drug pharmacokinetics in the mouth and oropharynx requires that we understand the 
interaction between bacteria, different oral and pharyngeal epithelial surfaces and saliva. A 
recent human study110 reported that bacteria can only survive in the mouth if they are 
attached to epithelial surfaces, that this bacteria-tissue binding is strong, and that most 
bacteria in saliva is attached to epithelial cells. There are no data available about this for 
oropharyngeal STIs, but it is plausible that for NG, ceftriaxone works via high concentrations 
in epithelial cells in the absence of detectable concentrations in saliva. Saliva is constantly 
being produced and epithelial cells lining the mouth are replaced every 2.7 hours, faster 
that the rate of bacterial growth. These data suggest two things. Firstly, drugs distributed in 
saliva will be swallowed (every minute) meaning there is short contact times between 
bacteria and drugs in saliva. Dosing at night when patients are asleep when there is lower 
saliva flow could potentially improve efficacy. Secondly, tissue or cell surface mucus 
concentrations111 are likely to be more important than saliva since bacteria, even those in 
saliva are constantly in contact with tissue. Furthermore, the longer the T1/2 of a drug, the 
longer it will be found in tissue and saliva and be less affected by the rapid cycling of 
epithelial tissue and saliva. Based on this, Tables 1 and 2 show that the pharmacokinetic 
properties (Vd, saliva-plasma ratio and T1/2) for azithromycin is greater than for most other 
antimicrobials used for treatment of STIs, which supports its antimicrobial value, particularly 






Different anatomical sites of infection may require different antimicrobials and/or dosing 
regimens for the same STI. For CT, current studies show that rectal infections derive 
substantially greater cure rates using doxycycline7 rather than azithromycin, although there 
are currently no RCT data to confirm this. Doxycycline also appears more effective than 
azithromycin for urogenital CT, although the differences in cure are much smaller. 41 As 
discussed above, there are many factors contributing to differences in antimicrobial efficacy 
by tissue site. This may be because antimicrobial concentrations vary by tissues, as seen 
with higher MIC values for CT in colorectal cells compared to in endocervical cells.43 It is 
possible that for pharyngeal NG, higher azithromycin doses may have higher efficacy.45 
Furthermore, for NG, dual therapy (ceftriaxone plus azithromycin) currently appears to 
provide high efficacy for all sites of infection17, 79, 112 and it appears effective at minimizing 
the spread of gonococcal AMR.79 However, the ideal doses or dosing regimens of 
ceftriaxone and azithromycin have not been established and other effective antimicrobial 
combinations might be possible. Hypothetically, high dose azithromycin (2 g) may be 
advantageous in combination with gentamicin 240 mg45 as these drugs target the 
intracellular and extracellular bacteria, respectively, thereby killing any intracellular 
organisms escaping to the extracellular space, minimizing the impact of sub-inhibitory levels 
of antimicriobials.66 A recent study also found that NG can evade the host innate immune 
response when co-infected with CT113 so the use of azithromycin with its high intracellular 
concentrations may benefit also dual infections.   
Given the lack of new drugs for STIs entering the market, optimization of current 
antimicrobials in relation to the dose, dosing regimen, and/or its use as part of combination 




NG, azithromycin still remains a useful option but higher doses (at least 2 g), possibly 
divided over a number of days, are likely required. Higher doses of at least 2 g total are 
probably resulting in higher concentrations for prolonged duration in all tissue sites and 
explain better cure rates for NG,45, 108 MG 56 and likely CT.114 These regimens should ideally 
be administered with front end loading doses (i.e. 1 g), which result in higher AUC and 
greater bacterial clearance and be administered over no more than 3 days (1 g, 500 mg, 500 
mg).40 Dividing the doses also reduces the risk of vomiting which can affect efficacy. 
However, higher doses result in a longer duration that an antimicrobial remains in the 
body after ending treatment and increase the duration of sub-inhibitory concentrations that 
could increase the risk for inducing or selecting resistance if index cases are re-exposed to 
bacteria when these are present. This is particularly relevant with azithromycin whose long 
T1/2 means that azithromycin after a 1.5 g dose divided on three consecutive days has been 
extrapolated, from detection in plasma in up to 14 days after administration, to be present 
in some body sites for up to 4 weeks.73 This problem has also been reported for  
Streptococcus pneumoniae exposed to sub-inhibitory azithromycin levels.115 For STIs, this is 
mainly a problem for risk groups who are at high risk of re-exposure to STIs within days to 
weeks following treatment. This risk of resistance emergence may be possible to mitigate by 
advising no, particularly unprotected, sexual intercourse for at least 2 weeks after 
completing therapy. However, in high risk groups the compliance to this advice may be 
limited, and the rates of condom use, especially in oral sex, are suboptimal in both 
heterosexual and MSM populations.  
The influence of pH remains a new area to explore as studies have shown disease 
(possibly inflammation) can alter the pH in both the mouth (saliva)116 and rectum30 of 




acid lowering drugs such as proton pump inhibitors.37 Finally, the effects of biofilm 
formation and clumping of bacteria on treatments of infections in different anatomical sites 
with STI antimicrobials are mainly unexplored.  
In conclusion, an enhanced understanding of the pharmacokinetics of current and 
future STI therapeutic antimicrobials is essential to guide appropriate STI treatment, 
particularly when there are few new antimicrobials in development.  Gaining detailed 
insights into the distribution and activity of drugs at the different anatomical sites of 
infection (oropharyngeal, urogenital and/or rectal) may show that site targeted therapies 
may be one new method in optimizing current treatment for emerging AMR infections.   
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